Advanced Search

 

Study ID Status Title Patient Level Data
104730 Completed A phase III, multicentre booster vaccination study to assess the immunogenicity, safety and reactogenicity of a dose of Mencevax™ ACWY at 24 to 30 months of age in subjects primed with an investigational vaccination regimen in study 100480 and boosted at 15 to 24 months of age in study 104727. Study Listed on ClinicalStudyDataRequest.com
104731 Completed Multicenter, Phase II Dosimetry/Validation Study of 131Iodine–Anti B1 (Murine) Radioimmunotherapy for Chemotherapy Refractory Low Grade B Cell Lymphomas and Low Grade Lymphomas that Have Transformed to Higher Grade Histologies Study Listed on ClinicalStudyDataRequest.com
104733 Completed Demonstrate lot-to-lot consistency of final production method of GSK Biologicals' Hib-MenAC vaccine mixed extemporaneously with Tritanrix™-HepB & demonstrate its non-inferiority vs Tritanrix™-HepB/Hiberix™ in healthy infants at 2, 4 and 6 months Study Listed on ClinicalStudyDataRequest.com
104743 Completed A Phase IIb randomized, double-blind, controlled study of the safety, immunogenicity and proof-of-concept of RTS,S/AS02A, and RTS,S/AS01B, two candidate malaria vaccines in malaria-experienced adults living in Western Kenya.
104745 Completed Phase III Vaccination Study for Evaluation of Immunogenicity and Reactogenicity of Influsplit SSW 2004/2005 in People age 18 or beyond Study Listed on ClinicalStudyDataRequest.com
104756 Completed Booster Vaccination Study to Assess Safety & Reactogenicity of a Dose of DTPw-HBV/Hib Vaccine and to Assess the Immunogenicity, Safety & Reactogenicity of a Dose of Mencevax™ ACW in Subjects Primed in Study 759346/007 Study Listed on ClinicalStudyDataRequest.com
104772 Completed Assess lot-to-lot consistency of GSK Biologicals' HPV-16/18 L1/AS04 vaccine following manufacturing adjustments administered intramuscularly according to a 0,1,6-mth schedule in healthy female subjects (18-25 y) Study Listed on ClinicalStudyDataRequest.com
104798 Completed A phase II study to assess the efficacy, immunogenicity and safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 (Cervarix TM) vaccine administered intramuscularly according to a 0, 1, 6 month schedule in healthy Japanese female subjects aged 20 - 25 years. Study Listed on ClinicalStudyDataRequest.com
104820 Completed A study to evaluate safety, immunogenicity and efficacy of GSK Biologicals HPV-16/18 L1/AS04 vaccine administered intramuscularly according to a three-dose schedule (0, 1, 6 month) in healthy adult female subjects aged 26 years and above Study Listed on ClinicalStudyDataRequest.com
104847 Completed A Study to Assess the Interaction of SB-480848 with Aspirin and/or Clopidogrel
104858 Completed A phase III, single-blind, randomized study to evaluate the immunogenicity and safety of Fluarix® (GSK Biologicals') compared with Fluzone® (Aventis Pasteur/Sanofi) administered intramuscularly in children (6 months and older) Study Listed on ClinicalStudyDataRequest.com
104864/111127 Completed An open-label, multicenter, non-comparative, Phase II study of oral topotecan in combination with bevacizumab for second-line treatment in subjects with relapsed small-cell Lung Cancer (SCLC)
104864/201 Completed A Phase III, Open-Label, Multicenter, Randomized, Comparative Study of Topotecan, Ara-C and G-CSF (TAG) versus Idarubicin, Ara-C and G-CSF (IDAG) in MDS Patients with RAEB (High-Risk), RAEB-t or in Patients with AML from a Preceding Phase of MDS
104864/250 Completed Phase I/II study of oral topotecan and intravenous paclitaxel in patients with advanced non-small cell lung cancer (phases I and II) and other advanced solid tumors (phase I only)
104864/386 Completed An open-label, multicenter, randomized, phase II study of 5-day oral topotecan vs. 21-day oral topotecan vs. CPT-11 (Irinotecan) for second-line therapy in patients with colorectal carcinoma
104864/396 Completed An open-label, multicentre, randomised, phase III comparator study of oral topotecan versus intravenous topotecan for second-line therapy in patients with SCLC who have relapsed greater than or equal to 90 days after completion of first-line therapy
104864/405 Completed An Open Label, Multicenter, Randomized, Phase II Study of Topotecan and Paclitaxel vs. Etoposide/Cisplatin as First Line Treatment in Patients with Extensive Disease Small Cell Lung Cancer
104864/410 Completed A randomised open-label multicentre Phase II study to evaluate the safety and efficacy of intravenous topotecan given with either cisplatin or etoposide every 21 days as first-line therapy in patients with extensive-disease (ED) small-cell lung cancer
104864/435 Completed A Phase II Study of Topotecan and Paclitaxel as First-Line Treatment in Patients with Extensive Disease Small Cell Lung Cancer
104864/438 Completed Phase I Study of Oral Topotecan in Patients with Hematological Myeloid Malignancies
104864/478 Completed An Open-Label, Multicentre, Randomised, Phase III Comparator Study of Active Symptom Control alone or in Combination with Oral Topotecan in Patients with Relapsed Resistant SCLC
104864/502 Completed An Open-Label, Multicenter, Randomized, Phase II Study of Oral Topotecan Daily x 5 Days vs. Oral Topotecan 5 Days On, 2 Days Off for 3 Weeks for Second-Line Treatment in Patients with Recurrent, Locally Advanced or Metastatic Cervical Cancer
104864/507 Completed Phase I Study of the Effect of Oral Cyclosporin A on the Pharmacokinetics of Oral Topotecan
104864/511 Completed A Phase I open label study to assess the safety, tolerability, and efficacy of oral etoposide and oral topotecan administered in combination to patients with small-cell lung cancer who have not previously received chemotherapy
104864/517 Terminated A Phase I study of oral topotecan as a radiosensitizing agent in patients with rectal cancer

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.